Affordable Access

deepdyve-link
Publisher Website

New Chalcone Derivative Inhibits ABCB1 in Multidrug Resistant T-cell Lymphoma and Colon Adenocarcinoma Cells.

Authors
  • Čižmáriková, Martina1
  • Takáč, Peter2
  • Spengler, Gabriella3
  • Kincses, Annamária3
  • Nové, Márta3
  • Vilková, Mária4
  • Mojžiš, Ján5
  • 1 Department of Pharmacology, Faculty of Medicine, University of Pavol Jozef Safarik, Kosice, Slovak Republic [email protected] [email protected]
  • 2 Institute of Human and Clinical Pharmacology, University of Veterinary Medicine and Pharmacy in Kosice, Kosice, Slovak Republic [email protected] [email protected]
  • 3 Department of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged, Szeged, Hungary. , (Hungary)
  • 4 Department of Organic Chemistry, Faculty of Science, University of Pavol Jozef Safarik, Kosice, Slovak Republic.
  • 5 Department of Pharmacology, Faculty of Medicine, University of Pavol Jozef Safarik, Kosice, Slovak Republic.
Type
Published Article
Journal
Anticancer Research
Publisher
International Institute of Anticancer Research
Publication Date
Dec 01, 2019
Volume
39
Issue
12
Pages
6499–6505
Identifiers
DOI: 10.21873/anticanres.13864
PMID: 31810914
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Development of new potential drugs to overcome multidrug resistance to chemotherapy is a big challenge for cancer treatment. Attention is also given to the natural compounds and their derivatives. The study aimed at evaluating the impact of a new chalcone derivative (1C) on multidrug resistant cell lines, focusing on P-glycoprotein (P-gp, ABCB1) inhibition, as well as 1C-doxorubicin interaction in vitro. Cytotoxic and antiproliferative effects of the 1C compound were assessed by thiazolyl blue tetrazolium bromide (MTT) method in mouse T-cell lymphoma and human colon adenocarcinoma cells expressing ABCB1. Alterations in ABCB1 activity were evaluated by rhodamine 123 accumulation assay using flow cytometry. Drug-drug interaction was studied using combination assay. Our results confirmed antiproliferative, cytotoxic, as well as ABCB1 inhibitory potential of 1C in both tested ABCB1-expressing cancer cell lines. Furthermore, 1C displayed synergistic interaction with doxorubicin. Our results suggest the 1C chalcone derivative as a promising compound against resistant lymphoma and colon cancer, which could be used in monotherapy or in combination with other chemotherapeutics. Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Report this publication

Statistics

Seen <100 times